Nanobiotix is transforming into a capital-light oncology platform focused on milestone and royalty revenues, centered on its JNJ-1900 program now led by Johnson & Johnson. JNJ-1900 aims to enhance radiotherapy across multiple solid tumors, with a potential $2.6 billion milestone structure and double-digit royalties. Recent financing and a planned equity raise in May 2026 extend Nanobiotix's cash runway through 2029, transferring much clinical and operational risk to J&J. While speculative, Nanobiotix offers upside if its radiotherapy platform gains broad adoption but faces risks including clinical trial outcomes, operational challenges, and dilution from fundraising.
Veea Inc. has announced the commercial release of VeeaONE, a full-stack AI infrastructure platform that integrates edge-to-cloud hardware and software. The platform supports VeeaWare middleware on NVIDIA Jetson and x86/Arm servers, enabling secure, l...
Virtuals Protocol has introduced customizable tokenized indexes on the Robinhood Chain, allowing users to combine multiple assets into a single token. This innovation enables users to create and manage their own asset baskets and earn fees when other...
US spot Bitcoin ETFs saw net inflows of $107.8 million on Wednesday, while Ethereum ETFs attracted $53.8 million, signaling renewed institutional interest in crypto funds. Since their launch in January 2024, Bitcoin ETFs have accumulated over $51 bil...
Kaia has signed a strategic partnership with Xilo Labs to integrate Mochi, an onchain asset management platform, into Kaia's ecosystem. This collaboration allows users to invest stablecoins into diversified portfolios backed by tokenized real-world a...
Bitcoin's price surged to nearly $65,000 following softer-than-expected U.S. inflation data for June, easing fears of Federal Reserve rate hikes. However, on-chain data reveals two main groups of investors—long-term holders who bought near last year'...
